Sanofi must pay up to $109M for Hyalgan kickbacks

Share this article:
Drugmakers Sanofi-Aventis U.S. Inc. and Sanofi-Aventis U.S. LCC will pay up to $109 million in a settlement over an alleged scheme to provide doctors with free units of its knee-injection drug Hyalgan in return for purchase of the treatment.

The action, which was announced Dec. 19, also settled claims that the Paris-based company reported an average sales price (ASP) that omitted the free units of the arthritis-related pain reliever between 2005 and 2009. That led to government overpayment on drug reimbursement rates for Hyalgan and the competing Supartz.

The penalty is the result of information from former Sanofi sales representative Mark Giddarie. The Department of Justice said Giddarie will receive $18.5 million as his share of the settlement proceeds. Multiple states will also share in the federal government's recovery.

Bridgewater, N.J.-based Sanofi US issued a statement saying it “is pleased to have reached a resolution” in the matter.

Share this article:

More in News

Hospitals in the Midwest refer patients to the broadest networks of skilled nursing facilities, study finds

Hospitals in the Midwest refer patients to the ...

Midwestern hospitals spread referrals to the greatest variety of skilled nursing facilities and tap their favorite SNFs least often, according to a recently published analysis of nationwide referral patterns.

Bill would affect pay, scheduling for some nursing home housekeeping staff

Nursing homes could face more stringent scheduling requirements for housekeeping workers and might be on the hook to compensate them for last-minute shift changes under a bill proposed in both houses of Congress.

Joint Commission adds memory care accreditation

New memory care accreditation for nursing homes encourages staff to use a flexible, problem-solving approach to care for those with dementia, according to Joint Commission guidelines.